Mr. Aras Azadian reports

AVICANNA AND NORTHERN GREEN CANADA EXECUTE MASTER SERVICE AGREEMENT TO OPERATIONALIZE MYMEDI.CA

Avicanna Inc. has entered into a master service agreement (MSA) with Northern Green Canada (NGC), a federally licensed, EU GMP (European Union good manufacturing practice) certified cannabis producer to operationalize MyMedi.ca medical cannabis care platform's logistics and fulfilment infrastructure.

Through the MSA, NGC will provide the MyMedi.ca medical cannabis care platform with regulatory support and access to appropriate Health Canada licenses in addition to services related to inventory management and quality assurance. NGC will also contribute to the MyMedi.ca medical cannabis care platform's formulary of products with its own EU GMP-certified proprietary genetics and finished products.

"We look forward to working with NGC to support patients in their journey and grow our medical cannabis care platform," said Aras Azadian, CEO, Avicanna. "NGC's established infrastructure and quality assurance expertise gives us confidence that they are the right choice as we aim to build upon the foundation initially developed by the Medical Cannabis by Shoppers team and further establish confidence in medical cannabis solutions by providing education, expanding coverage, and striving towards increased consistency in services."

"NGC has established a solid international footprint into the medicinal cannabis space, and we are thrilled to partner with Avicanna to expand our domestic business to reach more patients in Canada," said Lisa McCormack, Northern Green Canada's President, and CEO.

Shoppers Drug Mart(TM) ("Shoppers") has partnered with Avicanna, to transition its Medical Cannabis by Shoppers business and provide its patients access to a complete medical cannabis platform through MyMedi.ca. With the support of NGC, Avicanna is establishing MyMedi.ca as a comprehensive resource to support the medical community and the tens of thousands of patients currently authorized to access the Medical Cannabis by Shoppers platform.

Since the initial announcement between Shoppers and Avicanna, the Company has been coordinating with all stakeholders including the medical community, specialty clinics and leading Canadian licensed producers to ensure continuation of care for existing patients as they transition to MyMedi.ca. Additionally, Shoppers and Avicanna have collaborated to develop a seamless process related to the patient consent and transfer that will minimize effort required by patients and their healthcare providers.

To its knowledge, the Company carries out its operations in compliance with all applicable laws in the jurisdictions in which it operates.

About MyMedi.ca

MyMedi.ca is Avicanna's medical cannabis care platform that is formed with the aim to better serve medical cannabis patients' needs and enhance the patient journey. MyMedi.ca will feature scientifically curated products, patient support programs and educational resources to support the incorporation of medical cannabis into health care regimens.

About Avicanna Inc.

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development that has led to the commercialization of more than thirty products across various market segments:

Medical Cannabis & Wellness Products:

Marketed under the RHO Phyto(TM) brand these medical and wellness products are a line of pharmaceutical-grade cannabinoid products containing varying ratios of cannabidiol ("CBD") and tetrahydrocannabinol ("THC"). The product portfolio contains a full formulary of products including oral, sublingual, topical, and transdermal deliveries that have controlled dosing, enhanced absorption and stability studies supported by pre-clinical data. The formulary is marketed with consumer, patient and medical-community education and training.

Pharmaceutical Pipeline : Leveraging Avicanna's scientific platform, vertical integration, and real-world evidence, Avicanna has created a pipeline of patent-pending drug candidates that are indication-specific and in various stages of clinical development and commercialization. These cannabinoid-based drug candidates look to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders. Avicanna's first pharmaceutical preparation (Trunerox(TM)) is in the drug registration stage in South America.

MyMedi. ca Medical Cannabis Care Portal: An online platform designed to provide access to medical cannabis and enhance the patient journey through focus on patient education in areas such as harm reduction, providing specialty services to distinct patient groups such as veterans and reimbursement services for public and private providers. MyMedi.ca has pharmacist-led patient support programs and comprehensive training programs for the medical community along with a scientifically curated and diverse formulary of products with competitive pricing in collaboration with Canadian licensed producers.

We seek Safe Harbor.